In those rare moments when Roy Herbst isn't seeing a patient or assessing the results of his research, he's aware of the quickening pace of time. So much of his time has been absorbed with education, training, mulling choices, and making hard decisions, each with potential to twist his life in a new direction. Somewhere in between the classes, the residency, the research, and the promotions, 22 years have slipped by.
"How do you get where you are when you are constantly being pulled in so many directions?" wonders Herbst, an associate professor of thoracic/head and neck medical oncology at M.D. Anderson Cancer Center in Houston. "How do you get where you land?"
Herbst has landed at one of the nation's leading cancer centers as its principal investigator for Phase I clinical trials of Endostatin, an anti- angiogenesis drug that kills tumors by cutting off their blood supply. His timing ...
